Accurately staging prostate cancer changes treatment decisions, and conventional imaging often misses small metastatic deposits. Pylarify (piflufolastat F 18) brought PSMA-targeted PET into wider practice.
It binds PSMA, which is heavily overexpressed on prostate cancer cells, making suspected metastasis or biochemical recurrence visible on PET imaging. The intravenous fluorine-18 agent is approved to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer.
Pylarify became one of the most widely adopted PSMA PET agents in the U.S., helped by fluorine-18’s longer half-life, which suits centralized manufacturing and distribution. It faces direct competition from other PSMA tracers, making reimbursement and radiopharmacy logistics the decisive factors to track.
